Siatis Perry C 4
4 · AbbVie Inc. · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
AbbVie (ABBV) EVP Perry C. Siatis Exercises Options, Sells Shares
What Happened Perry C. Siatis, EVP, General Counsel and Secretary of AbbVie, exercised employee stock options for a total of 22,381 shares on Feb 25, 2026 and sold those 22,381 shares the same day in an open-market transaction. The exercises were in three tranches: 7,314 shares at $149.62 (exercise cost $1,094,321), 7,775 shares at $175.28 (exercise cost $1,362,802), and 7,292 shares at $192.86 (exercise cost $1,406,335) — aggregate exercise cost $3,863,458. The 22,381 shares were sold in the open market at $230.00 per share for total proceeds of $5,147,630 (filed on Feb 27, 2026). The filing also reports corresponding derivative dispositions tied to the option exercises. This pattern indicates a same-day exercise-and-sell (cashless exercise) rather than a new long-term purchase.
Key Details
- Transaction date: 2026-02-25; Filing date: 2026-02-27 (timely filing).
- Exercises (M): 7,314 @ $149.62; 7,775 @ $175.28; 7,292 @ $192.86 — total exercise cost $3,863,458.
- Sale (S): 22,381 shares @ $230.00 — total proceeds $5,147,630.
- Net cash difference (sale proceeds minus exercise cost) ≈ $1,284,172 (before taxes/fees).
- Shares owned after transaction: not specified in the provided excerpt—see the full Form 4 for total beneficial ownership.
- Footnotes: all options were granted under the AbbVie Amended & Restated 2013 Incentive Stock Program and are reportable as transactions exempt from Section 16 under Rule 16b-3; vesting schedules for the tranches are noted in the filing.
Context
- The filings show an exercise of vested employee options followed by an immediate sale of the resulting shares — a common way for insiders to realize value and cover exercise costs/taxes. This is generally considered routine insider liquidity rather than a directional buy signal.
- “M” denotes option exercise; the matching sale of 22,381 shares matches the total exercised shares, confirming the cashless-like pattern.
- No 10b5-1 plan, gift, or late-filing indication was noted in the provided data; the report appears timely based on transaction and filing dates.
Insider Transaction Report
- Exercise/Conversion
Common Stock, $0.01 par value
2026-02-25$149.62/sh+7,314$1,094,321→ 45,451 total - Exercise/Conversion
Common Stock, $0.01 par value
2026-02-25$175.28/sh+7,775$1,362,802→ 53,226 total - Exercise/Conversion
Common Stock, $0.01 par value
2026-02-25$192.86/sh+7,292$1,406,335→ 60,518 total - Sale
Common Stock, $0.01 par value
2026-02-25$230.00/sh−22,381$5,147,630→ 38,137 total - Exercise/Conversion
Option (Right to buy)
[F1]2026-02-25$149.62/sh−7,314$1,094,321→ 0 totalExercise: $149.62Exp: 2033-02-15→ Common Stock (7,314 underlying) - Exercise/Conversion
Option (Right to buy)
[F2]2026-02-25$175.28/sh−7,775$1,362,802→ 7,774 totalExercise: $175.28Exp: 2034-02-14→ Common Stock (7,775 underlying) - Exercise/Conversion
Option (Right to buy)
[F3]2026-02-25$192.86/sh−7,292$1,406,335→ 14,583 totalExercise: $192.86Exp: 2035-02-12→ Common Stock (7,292 underlying)
Footnotes (3)
- [F1]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026.
- [F2]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,775 on February 15, 2025 and 7,775 on February 15, 2026, and becomes exercisable as to 7,774 shares on February 15, 2027.
- [F3]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,292 shares on February 13, 2026 and becomes exercisable in annual increments of 7,292 on February 13, 2027, and 7,291 on February 13, 2028.